gdc
Breast CancerFDA Approvals, News & UpdatesNewsworthy

Neratinib First Long-Term Adjuvant Therapy for Early-Stage, HER2-Positive Breast Cancer

On July 17, 2017, the FDA approved Nerlynx (neratinib; from Puma Biotechnology) for long-term adjuvant treatment of early-stage, HER2-positive breast cancer in patients who received previous therapy with Herceptin (trastuzumab).
December 2017 Vol 3 No 6

On July 17, 2017, the FDA approved Nerlynx (neratinib; from Puma Biotechnology) for long-term adjuvant treatment of early-stage, HER2-positive breast cancer in patients who received previous therapy with Herceptin (trastuzumab). Nerlynx, a kinase inhibitor that blocks enzymes that promote cell growth (including cancer cells), is taken after breast cancer treatment to reduce the risk of the cancer coming back.

“HER2-positive breast cancers are aggressive tumors and can spread to other parts of the body, making adjuvant therapy an important part of the treatment plan. Now, these patients have an option after initial treatment that may help keep the cancer from coming back,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The approval of Nerlynx was based on a clinical trial of patients who had completed Herceptin therapy in the past 2 years. After 2 years, 94% of patients who used Nerlynx were alive and their cancer did not come back compared with 92% of patients who received a placebo.

The most common side effects of Nerlynx include diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, muscle spasms, dyspepsia, liver damage, nail and skin disorders, weight loss, and urinary tract infection.

Recommended For You
Breast CancerSurvivorship
Surviving Pregnancy and Breast Cancer
By Kelsey Moroz

Many cancer doctors will tell you not to have coffee or sushi when you are pregnant, but what about cancer treatment? When Jamie Ledezma was wrapping up the first trimester of her first (and only) pregnancy, she was diagnosed with breast cancer.

Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.

Last modified: February 28, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country